Budget reductions in Europe are leading to fewer cataract procedures, and the weak economy could lead to more cutbacks.
This year’s meeting looked at the science behind minimally invasive glaucoma surgery (MIGS) and debated the classification of techniques.
The stent is the first such device approved for use in combination with cataract surgery to reduce IOP in adult patients with mild or moderate open-angle glaucoma.
Medications are still the focus for treating glaucoma patients, according to a recent Market Scope survey of US glaucoma specialists.
Global revenues will reach $1.1 billion in 2012, with ultrasonic phaco machines, dedicated machine packs, and accessories making up 86 percent of revenues.
This month's news includes the latest from QLT Inc., Abbott Medical Optics, Bausch + Lomb, LensAR, Alimera Sciences, Optimedica, Mobius Therapeutics, and StemCell's, Inc.
You are not currently logged in.
©2017 Market Scope
Lost your Password